Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
Eton Pharmaceuticals (Nasdaq: ETON) announced that CEO Sean Brynjelsen will present at the LD Micro Main Event XV Conference on October 26, 2022, at 6:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) announced that CEO Sean Brynjelsen will present at the LD Micro Main Event XV Conference on October 26, 2022, at 6:00 PM ET. The event will be available via webcast on the company's website in the Investors section. Eton focuses on developing treatments for rare diseases and currently markets ALKINDI SPRINKLE® and Carglumic Acid tablets, with several additional products under development. For more information, visit www.etonpharma.com.
Details
News Market Reaction – ETON
The recorded move for ETON in the trading session of this news was +3.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the LD Micro Main Event XV Conference as follows:
| Date: | Wednesday, October 26, 2022 |
| Time: | 6:00PM ET |
| Register to watch the event here: | Click Here |
The webcast will be accessible via the Company’s website at https://ir.etonpharma.com/ in the Investors section under Events and Presentations.
Eton will be participating in 1x1 meetings, which can be requested through your LD Micro representative.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases. The Company currently commercializes ALKINDI SPRINKLE® and Carglumic Acid tablets and has four additional rare disease products under development, including dehydrated alcohol injection and the ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.